There is a study[0] showing cross-reactivity between SARS-CoV-2 antibodies and other human tissues, thus predisposing the host to autoimmune diseases. This should apply even more so to any vaccine since vaccines produce a more robust immune response.
Phase 2/3 of Pfizer-BioNTech did, however, include people with autoimmune diseases [1]. Other vaccine trials did not, as far as I am aware. This does not really shine a light on pre-disposition to an autoimmune disease 6-9-12 mo down the road.
Reading this comment again before I post made me realize it sounds very gloomy, so I feel obliged to say I'll be getting whatever vaccine I can get my hands on at the soonest possible date.
[0] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246018/#__ffn_...
> There is a study[0] showing cross-reactivity between SARS-CoV-2 antibodies and other human tissues, thus predisposing the host to autoimmune diseases. This should apply even more so to any vaccine since vaccines produce a more robust immune response.
Since the antibody tested in the study was a commercial, monoclonal one, this is somewhat hard to assess. But I think you’re right given what they found in the blood tests.
> This does not really shine a light on pre-disposition to an autoimmune disease 6-9-12 mo down the road.
Autoimmune reactions should happen in the short run, right?
I believe Pandermix took 6 months for narcolepsy to develop.
The narcolepsy issue was never going to be uncovered before it was rolled out large scale.
the onset judged by "first contact to health care" was much earlier.
It is at this point that I remind myself of all the other dangerous things that I do: driving, motorcycling, rock climbing, skiing, etc.
The risk of long term side effects is worth the benefit of spinning up the global economy again.
―https://en.wikipedia.org/wiki/Cross-reactivity#Applications_...
EDIT: The mRNA vaccines are obviously not therapeutic antibodies, but they probably checked for cross-reactivity of the engineered spike protein as well as the generated antibodies using similar methods. I’m not 100% sure, though.